In November 2026, the FDA sent out a Drug Safety Communication, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition" that some drug safety observers would say was overdue. For example, this recent Drug Injury Law article about NAION … [Read more...]
GLP-1 RA Drug NAION Cases: Medical and Legal Updates October 2025
GLP-1 RA Drug NAION Cases: Possible Drug Injury Lawsuits We are investigating possible drug injury lawsuits where people using glucagon-like peptide-I receptor agonist (GLP-1 RA) drugs were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), resulting in vision loss or blindness. Those GLP-1 RA drug NAION cases involve these … [Read more...]